IBD

Harvard-Led Researchers Pursuing Innovative, Non-Toxic IBD Treatment

Apr 13, 2019 | IBD, Myosin Light Chain Kinase (MLCK)

Researchers from Harvard Medical School First Affiliated Hospital of Soochow University and the University of Chicago are in hot pursuit of an innovative, non-toxic method to explore Irritable Bowel Disease as well as other conditions that impact gastrointestinal...

U.S. & Chinese Research Team Pursue Novel and Nontoxic IBD Treatment

Apr 4, 2019 | IBD

A Sino-American research team is delving into an enzyme known as the myosin light chain (MLCK). Apparently, it serves a key function in the regulation of the epithelial barrier and possibly associate with gastrointestinal inflammation. The team is represented by a...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Harvard-Led Researchers Pursuing Innovative, Non-Toxic IBD Treatment

U.S. & Chinese Research Team Pursue Novel and Nontoxic IBD Treatment

Pin It on Pinterest